06.18.2020
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
- Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing...
News & Insights
Emergent CDMO News, Insights & Events
When a company develops, manufactures and delivers vaccines and therapeutics that take on the most serious global health threats, it’s not surprising to see their name in the headlines. And we are honored that for more than 20 years, Emergent has been one of those names. Included below are prominent news and feature stories that profile a range of our accomplishments through the years as well as advancements we’ve made in the technologies, processes and expertise needed to serve as a premier CDMO.
06.17.2020
Editorial: Good Manufacturing Practices: Challenges with Compliance
Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm...
06.02.2020
Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines
Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...
06.01.2020
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
- Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
04.27.2020
May 4th Webinar: Rapid Readiness for Pandemic Response
Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic...
04.27.2020
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)
Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...